GPs resistant over smoking advice
Are the days numbered for use of ß-blockers in hypertension?
Blood pressure arm of ASCOT trial stopped a year early after finding an ACE inhibitor plus calcium channel blocker had ‘substantial benefits' over a
ß-blocker and diuretic
LIFE trial of more than 9,000 patients found risk of dying from stroke was 35 per cent lower with an ARB than a ß-blocker
More results from the ASCOT trial are unveiled at the American College of Cardiology meeting in Orlando showing that an ACE inhibitor and calcium channel blocker could cut all-cause mortality by 15 per cent compared with a diuretic and ß-blocker; NICE and BHS announce they are to hold a high-level meeting to issue new guidance when results are published
SeptemberFormal release of ASCOT data prompts NICE to announce it will review its guidance in light of the data